Skip to main content

News Releases

Menu
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
December 16, 2019
Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium Download PDF format download (opens in new window)
November 13, 2019
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy Download PDF format download (opens in new window)
November 7, 2019
Clovis Oncology Announces Third Quarter 2019 Operating Results Download PDF format download (opens in new window)
October 22, 2019
Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7 Download PDF format download (opens in new window)
October 11, 2019
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund Download PDF format download (opens in new window)
September 29, 2019
Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019 Download PDF format download (opens in new window)
September 23, 2019
Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals Download PDF format download (opens in new window)
September 12, 2019
Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019 Download PDF format download (opens in new window)
August 28, 2019
Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference Download PDF format download (opens in new window)
August 22, 2019
Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Download PDF format download (opens in new window)
August 8, 2019
Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes Download PDF format download (opens in new window)
August 7, 2019
Clovis Oncology to Offer $225 Million of Convertible Senior Notes Download PDF format download (opens in new window)
August 1, 2019
Clovis Oncology Announces Second Quarter 2019 Operating Results Download PDF format download (opens in new window)
July 18, 2019
Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1 Download PDF format download (opens in new window)
June 6, 2019
Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair Download PDF format download (opens in new window)
June 1, 2019
Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting Download PDF format download (opens in new window)
May 20, 2019
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer Download PDF format download (opens in new window)
May 16, 2019
Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting Download PDF format download (opens in new window)
May 7, 2019
Clovis Oncology Announces First Quarter 2019 Operating Results Download PDF format download (opens in new window)
May 6, 2019
Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019 Download PDF format download (opens in new window)
May 2, 2019
Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million Download PDF format download (opens in new window)
April 24, 2019
Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7 Download PDF format download (opens in new window)
April 2, 2019
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019 Download PDF format download (opens in new window)
March 19, 2019
Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting Download PDF format download (opens in new window)
March 16, 2019
Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress Download PDF format download (opens in new window)
March 6, 2019
Clovis Oncology to Present at the Barclays Global Healthcare Conference Download PDF format download (opens in new window)
March 4, 2019
Clovis Oncology Announces Availability of Rubraca®▼ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany Download PDF format download (opens in new window)
February 26, 2019
Clovis Oncology Announces 2018 Operating Results Download PDF format download (opens in new window)
February 22, 2019
Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference Download PDF format download (opens in new window)
February 19, 2019
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies Download PDF format download (opens in new window)
February 12, 2019
Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26 Download PDF format download (opens in new window)
January 24, 2019
Clovis Oncology Announces European Commission Authorization of Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer Download PDF format download (opens in new window)
January 7, 2019
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018 Download PDF format download (opens in new window)
January 2, 2019
Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference Download PDF format download (opens in new window)